Newly formulated GROWJECT
bioequivalence
human GH
injection site pain
phosphate buffer
Journal
Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology
ISSN: 0918-5739
Titre abrégé: Clin Pediatr Endocrinol
Pays: Japan
ID NLM: 9433330
Informations de publication
Date de publication:
2021
2021
Historique:
received:
25
05
2020
accepted:
04
09
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
ppublish
Résumé
Daily treatment with subcutaneous injections of recombinant human GH can be physically and emotionally stressful for children and their caregivers owing to the pain caused by injection. In this study, 52 healthy male subjects were randomized to investigate the bioequivalence and compare the safety and injection-associated pain between the prior GROWJECT
Identifiants
pubmed: 33446950
doi: 10.1297/cpe.30.35
pii: 2020-0028
pmc: PMC7783130
doi:
Types de publication
Journal Article
Langues
eng
Pagination
35-40Informations de copyright
2021©The Japanese Society for Pediatric Endocrinology.
Déclaration de conflit d'intérêts
This clinical study was fully sponsored by JCR Pharmaceuticals, Co., Ltd.
Références
Patient Prefer Adherence. 2019 Feb 22;13:351-361
pubmed: 30863023
Rheumatol Ther. 2019 Jun;6(2):245-254
pubmed: 30915626
J Pharm Pharmacol. 1996 Oct;48(10):1012-5
pubmed: 8953501